(Q40824415)

English

Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials

scientific article published on January 1999

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

24 September 2017

0 references

Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials (English)

1 reference

Europe PubMed Central

24 September 2017

0 references

0 references

1 reference

based on heuristic

inferred from title

author name string

S Leucht

1

1 reference

Europe PubMed Central

24 September 2017

G Pitschel-Walz

2

1 reference

Europe PubMed Central

24 September 2017

D Abraham

3

1 reference

Europe PubMed Central

24 September 2017

W Kissling

4

1 reference

Europe PubMed Central

24 September 2017

language of work or name

0 references

publication date

1 January 1999

1 reference

Europe PubMed Central

24 September 2017

Schizophrenia Research

1 reference

Europe PubMed Central

24 September 2017

35

1 reference

Europe PubMed Central

24 September 2017

51-68

1 reference

Europe PubMed Central

24 September 2017

1

1 reference

Europe PubMed Central

24 September 2017

Treatment of schizophrenic disorders: Algorithms for acute pharmacotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2898%2900105-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Negative symptoms in schizophrenia. Definition and reliability

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2898%2900105-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Multiple fixed doses of "Seroquel" (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. The Seroquel Trial 13 Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2898%2900105-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Significance of neuroleptic dose and plasma level in the pharmacological treatment of psychoses

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2898%2900105-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Olanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trial

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2898%2900105-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2898%2900105-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Olanzapine versus haloperidol: acute phase results of the international double-blind olanzapine trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2898%2900105-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical efficacy of serotonin-dopamine antagonists relative to classic neuroleptics

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2898%2900105-4

7 January 2021

based on heuristic

inferred from DOI database lookup

ICI 204,636, an atypical antipsychotic: efficacy and safety in a multicenter, placebo-controlled trial in patients with schizophrenia. U.S. SEROQUEL Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2898%2900105-4

7 January 2021

based on heuristic

inferred from DOI database lookup

New dimensions in the pharmacologic treatment of schizophrenia and related psychoses

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2898%2900105-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Risperidone in the treatment of negative symptoms of schizophrenia: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2898%2900105-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment of negative symptoms

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2898%2900105-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Will the new antipsychotics bring hope of reducing the risk of developing extrapyramidal syndromes and tardive dyskinesia?

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2898%2900105-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Risperidone versus haloperidol in the treatment of chronic schizophrenic inpatients: a multicentre double-blind comparative study

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2898%2900105-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Molecular pathology of schizophrenia: more than one disease process?

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2898%2900105-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Risperidone versus haloperidol: I. Meta-analysis of efficacy and safety

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2898%2900105-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Important issues in the drug treatment of schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2898%2900105-4

7 January 2021

based on heuristic

inferred from DOI database lookup

ICI 204,636, a novel, atypical antipsychotic: early indication of safety and efficacy in patients with chronic and subchronic schizophrenia.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2898%2900105-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Drug treatment of schizophrenia in the 1990s. Achievements and future possibilities in optimising outcomes

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2898%2900105-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Negative and deficit symptoms in schizophrenia do respond to neuroleptics

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2898%2900105-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Risperidone versus clozapine in the treatment of schizophrenic patients with acute symptoms: a double blind, randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2898%2900105-4

7 January 2021

based on heuristic

inferred from DOI database lookup

A double-blind comparative study of clozapine versus chlorpromazine on Chinese patients with treatment-refractory schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2898%2900105-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Risperidone versus perphenazine in the treatment of chronic schizophrenic patients with acute exacerbations

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2898%2900105-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Risperidone versus zuclopenthixol in the treatment of acute schizophrenic episodes: a double-blind parallel-group trial

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2898%2900105-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Mechanism of the antipsychotic effect in the treatment of acute schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2898%2900105-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Olanzapine: a new antipsychotic agent with efficacy in the management of schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2898%2900105-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2898%2900105-4

7 January 2021

based on heuristic

inferred from DOI database lookup

The positive and negative syndrome scale (PANSS) for schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2898%2900105-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Symptoms in neuroleptic-naive, first-episode schizophrenia: response to risperidone

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2898%2900105-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical experience in developing treatment regimens with the novel antipsychotic risperidone.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2898%2900105-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Discrepancies between meta-analyses and subsequent large randomized, controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2898%2900105-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Risperidone in the treatment of schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2898%2900105-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Risperidone: how good is the evidence for efficacy?

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2898%2900105-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Optimal dose of neuroleptic in acute schizophrenia. A controlled study of the neuroleptic threshold and higher haloperidol dose

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2898%2900105-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Quetiapine ('Seroquel'); an effective and well-tolerated atypical antipsychotic

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2898%2900105-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Risperidone versus haloperidol in the treatment of chronic schizophrenic patients: a parallel group double-blind comparative trial

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2898%2900105-4

7 January 2021

based on heuristic

inferred from DOI database lookup

A path-analytical approach to differentiate between direct and indirect drug effects on negative symptoms in schizophrenic patients. A re-evaluation of the North American risperidone study

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2898%2900105-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. Risperidone Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2898%2900105-4

7 January 2021

based on heuristic

inferred from DOI database lookup

A comparison of quetiapine and chlorpromazine in the treatment of schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2898%2900105-4

7 January 2021

based on heuristic

inferred from DOI database lookup

What is an atypical antipsychotic?

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2898%2900105-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Dosage of haloperidol for schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2898%2900105-4

7 January 2021

based on heuristic

inferred from DOI database lookup

A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2898%2900105-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Extrapyramidal symptoms in patients treated with risperidone

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2898%2900105-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Quetiapine in patients with schizophrenia. A high- and low-dose double-blind comparison with placebo. Seroquel Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2898%2900105-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Risperidone in the treatment of schizophrenia: a meta-analysis of randomized controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2898%2900105-4

7 January 2021

based on heuristic

inferred from DOI database lookup

The new generation of antipsychotic drugs.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2898%2900105-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2898%2900105-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Negative symptoms: a path analytic approach to a double-blind, placebo- and haloperidol-controlled clinical trial with olanzapine

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2898%2900105-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2898%2900105-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Risperidone: efficacy and safety

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2898%2900105-4

7 January 2021

based on heuristic

inferred from DOI database lookup

A randomized, controlled, dose-ranging trial of sertindole in patients with schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2898%2900105-4

7 January 2021

based on heuristic

inferred from DOI database lookup

A controlled dose comparison of haloperidol in newly admitted schizophrenic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2898%2900105-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Clozapine versus typical neuroleptic medication for schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2898%2900105-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Sertindole Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2898%2900105-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0920-9964(98)00105-4

1 reference

Europe PubMed Central

24 September 2017

1 reference

Europe PubMed Central

24 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40824415&oldid=1908249874"